Chronic pain exerts an enormous personal and economic burden, affecting more than 30%
of people worldwide according to some studies. Unlike acute pain, which carries survival …

Replicated international studies have underscored the human and societal costs associated
with major depressive disorder. Despite the proven efficacy of monoamine-based …

The 21st century is characterized by an increasing incidence and prevalence of obesity and
the burden of its associated comorbidities, especially cardiometabolic diseases, which are …

Cancer is amenable to low-cost treatments, given that it has a significant metabolic
component, which can be affected through diet and lifestyle change at minimal cost. The …

Background Low-dose naltrexone is used to treat fibromyalgia despite minimal evidence for
its efficacy. This trial aimed to investigate whether 12-week treatment with 6 mg low-dose …

Abstract Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a devastating
disease affecting millions of people worldwide. Due to the 2019 pandemic of coronavirus …

Exposure to stressful stimuli activates kappa opioid receptor (KOR) signaling, a process
known to produce aversion and dysphoria in humans and other species. This endogenous …

Introduction Pharmacotherapeutic options continue to expand for the treatment of chronic
non-cancer pain. There has been an increasing emphasis on multimodal analgesia. This …

Objectives: While opioids temporarily alleviate pain, the overshoot of balancing pain drivers
may increase pain, leading to opioid induced hyperalgesia (OIH). Our goal was to find out …

Current pharmacologic treatments may provide limited analgesia in fibromyalgia and other
chronic pain disorders. Low-dose naltrexone (LDN) has emerged as a potential analgesic …